INDP Insider Trading Activity and SEC Form 4 Filings
INDP insider trading summary
No open-market insider purchases or sales of Indaptus Therapeutics, Inc. (INDP) have been reported on SEC Form 4 in the past 12 months.
Latest INDP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 14, 2023 | Glen R. Anderson | 10% Owner | Buy | $56K (23,934 @ $2.34) |
| Aug 11, 2023 | Glen R. Anderson | 10% Owner | Buy | $74K (35,064 @ $2.12) |
| Aug 10, 2023 | Glen R. Anderson | 10% Owner | Buy | $86K (44,354 @ $1.94) |
| Dec 1, 2022 | Boyan Vesselinov Litchev | Chief Medical Officer | Buy | $935 (500 @ $1.87) |
| Nov 22, 2022 | Boyan Vesselinov Litchev | Chief Medical Officer | Buy | $915 (500 @ $1.83) |
| Nov 21, 2022 | Jeffrey A Meckler | CEO and Director | Buy | $18K (9,600 @ $1.90) |
| Nov 18, 2022 | Jeffrey A Meckler | CEO and Director | Buy | $705 (400 @ $1.76) |
| Sep 8, 2022 | Jeffrey A Meckler | CEO and Director | Buy | $29K (10,308 @ $2.80) |
| Sep 7, 2022 | Jeffrey A Meckler | CEO and Director | Buy | $22K (8,632 @ $2.57) |
| Sep 7, 2022 | Walt Addison Linscott | Chief Business Officer | Buy | $393 (150 @ $2.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.